BR0316523A - Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente - Google Patents

Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente

Info

Publication number
BR0316523A
BR0316523A BR0316523-0A BR0316523A BR0316523A BR 0316523 A BR0316523 A BR 0316523A BR 0316523 A BR0316523 A BR 0316523A BR 0316523 A BR0316523 A BR 0316523A
Authority
BR
Brazil
Prior art keywords
peptides
patient
treating
compound
pharmaceutical composition
Prior art date
Application number
BR0316523-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Amy L Allan
Stephanie A Hopkins
Patricia L Gladstone
Graham Parry
Marian L Plunkett
Robert J Ternansky
Won Hyung Yoon
Fernando Donate
Andrew Mazar
Sean M O'hare
Original Assignee
Attenuon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon Llc filed Critical Attenuon Llc
Publication of BR0316523A publication Critical patent/BR0316523A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BR0316523-0A 2002-11-25 2003-11-25 Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente BR0316523A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42917402P 2002-11-25 2002-11-25
US47553903P 2003-06-02 2003-06-02
PCT/US2003/038175 WO2004047771A2 (en) 2002-11-25 2003-11-25 Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof

Publications (1)

Publication Number Publication Date
BR0316523A true BR0316523A (pt) 2005-10-18

Family

ID=32397181

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0316523-0A BR0316523A (pt) 2002-11-25 2003-11-25 Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
BR0316550-7A BR0316550A (pt) 2002-11-25 2003-11-25 Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente, e para detectar câncer em um paciente

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0316550-7A BR0316550A (pt) 2002-11-25 2003-11-25 Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente, e para detectar câncer em um paciente

Country Status (14)

Country Link
US (2) US7517855B2 (enExample)
EP (2) EP1569678A4 (enExample)
JP (2) JP2006514116A (enExample)
KR (2) KR20050096917A (enExample)
AU (2) AU2003298726A1 (enExample)
BR (2) BR0316523A (enExample)
CA (2) CA2507045A1 (enExample)
EA (2) EA200500871A1 (enExample)
HR (2) HRP20050584A2 (enExample)
MX (2) MXPA05005469A (enExample)
NO (2) NO20053111L (enExample)
NZ (2) NZ540363A (enExample)
PL (2) PL377763A1 (enExample)
WO (2) WO2004047771A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047771A2 (en) * 2002-11-25 2004-06-10 Attenuon, Llc. Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
EP1766405A1 (en) * 2004-05-21 2007-03-28 MDS Inc. doing Business Through Its MDS Pharma Services Division Method of quantifying the cell-binding properties of a medical device
US20060078535A1 (en) * 2004-10-13 2006-04-13 The Regents Of The University Of Michigan Anticancer compounds and methods
JP2008528635A (ja) 2005-02-01 2008-07-31 アテニュオン，エルエルシー Ａｃ−ＰＨＳＣＮ−ＮＨ２の酸付加塩
KR20070100832A (ko) * 2005-02-01 2007-10-11 아테뉴온, 엘엘씨 항혈관신생 ｐｈｓｃｎ 펩티드를 함유하는 조성물
CA2668500C (en) * 2006-11-08 2018-07-31 Chongxi Yu Transdermal delivery systems of peptides and related compounds
AU2016213759B2 (en) * 2006-11-08 2018-03-29 Chongxi Yu Transdermal delivery systems of peptides and related compounds
EP4067370A1 (en) 2009-05-08 2022-10-05 Chongxi Yu High penetration prodrug compositions of peptides and peptide related compounds
KR101228668B1 (ko) 2010-09-17 2013-01-31 가톨릭대학교 산학협력단 혈관신생 억제 활성을 갖는 펩타이드 및 이의 용도
GB2510488B (en) 2011-06-23 2020-04-08 Univ Texas Identifying peptides at the single molecule level
US11435358B2 (en) 2011-06-23 2022-09-06 Board Of Regents, The University Of Texas System Single molecule peptide sequencing
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
EP2846847B1 (en) * 2012-05-11 2020-03-25 C.P. Medical Corporation Biocompatible hydrogel treatments for retinal detachment
CA2875369C (en) 2012-06-04 2017-11-21 Suncor Energy Inc. Formulations containing paraffinic oil and anti-settling agent
EP2967056B1 (en) 2013-03-15 2018-02-21 Suncor Energy Inc. Herbicidal compositions
JP5970439B2 (ja) * 2013-09-20 2016-08-17 チョンシー ユー ペプチド及び関連化合物の経皮送達システム
EP3543703A1 (en) * 2014-09-15 2019-09-25 Board of Regents, The University of Texas System Improved single molecule peptide sequencing
EP3821010A4 (en) 2018-07-12 2022-04-20 Board of Regents, The University of Texas System Molecular neighborhood detection by oligonucleotides
JP7588289B2 (ja) 2019-02-15 2024-11-22 ニュートリエン・エージー・ソリューションズ・（カナダ）・インコーポレイテッド 植物の健康を増進するプロトポルフィリンｉｘ誘導体及びその使用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
EP0051682B1 (en) * 1980-05-13 1984-09-05 Mitsubishi Kasei Corporation Cysteine derivatives and process for their preparation
US4440788A (en) * 1980-05-13 1984-04-03 Mitsubishi Chemical Industries, Limited Cysteine derivatives
US4394519A (en) * 1982-01-19 1983-07-19 Research Corporation Amino acid blocking agents
GB8504253D0 (en) * 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US5229366A (en) * 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
US5149801A (en) * 1990-11-21 1992-09-22 The Regents Of The University Of California Boronated porphyrin compounds
US5561220A (en) * 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5556609A (en) * 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
US5608110A (en) * 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
ZA962077B (en) * 1995-03-14 1997-03-26 Siemens Ag Ultrasonic atomizer device with removable precision dosating unit
JP3142577B2 (ja) * 1995-03-14 2001-03-07 シーメンス アクチエンゲゼルシヤフト 着脱自在な精密計量供給ユニット
US5618513A (en) * 1995-06-07 1997-04-08 Mallinckrodt Medical, Inc. Method for preparing radiolabeled peptides
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
EP0927045B1 (en) * 1996-09-10 2005-12-14 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
US6331409B1 (en) * 1996-11-21 2001-12-18 The Regents Of The University Of Michigan Methods and compositions for wound healing
US6001965A (en) * 1996-11-21 1999-12-14 The Regents Of The University Of Michigan Anticancer compounds and methods
US6025150A (en) * 1996-11-21 2000-02-15 The Regents Of The University Of Michigan Methods and compositions for wound healing
WO1998030538A1 (en) * 1997-01-14 1998-07-16 Kaneka Corporation Process for producing cysteine derivatives
US5994309A (en) * 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
DE69839844D1 (de) * 1997-09-10 2008-09-18 Burnham Inst Verfahren zur auffindung von zielsuchenden verbindungen spezifisch für angiogenese vaskulatur
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
WO2000009537A2 (en) * 1998-08-14 2000-02-24 Administrators Of The Tulane Educational Fund Compounds having growth hormone releasing activity
DE60221115T2 (de) 2001-01-18 2008-03-13 The Regents Of The University Of Michigan, Ann Arbor Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
WO2004047771A2 (en) * 2002-11-25 2004-06-10 Attenuon, Llc. Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof

Also Published As

Publication number Publication date
NO20053111D0 (no) 2005-06-24
NZ540889A (en) 2008-09-26
NZ540363A (en) 2007-11-30
PL377701A1 (pl) 2006-02-06
NO20053112L (no) 2005-08-05
WO2004063213A3 (en) 2005-03-03
EP1594521A2 (en) 2005-11-16
NO20053111L (no) 2005-08-24
HRP20050585A2 (en) 2006-02-28
EP1594521A4 (en) 2008-01-09
US20050020810A1 (en) 2005-01-27
EP1569678A4 (en) 2008-01-02
MXPA05005545A (es) 2005-10-18
WO2004047771A3 (en) 2005-09-15
US20040162239A1 (en) 2004-08-19
US7517855B2 (en) 2009-04-14
PL377763A1 (pl) 2006-02-20
KR20050097494A (ko) 2005-10-07
HRP20050584A2 (hr) 2006-04-30
KR20050096917A (ko) 2005-10-06
BR0316550A (pt) 2005-10-04
AU2003298726A1 (en) 2004-08-10
MXPA05005469A (es) 2005-09-08
EA200500871A1 (ru) 2006-04-28
WO2004063213A2 (en) 2004-07-29
JP2006514116A (ja) 2006-04-27
JP2006515866A (ja) 2006-06-08
NO20053112D0 (no) 2005-06-24
CA2507045A1 (en) 2004-06-10
AU2003297609A1 (en) 2004-06-18
EA200500870A1 (ru) 2006-04-28
EP1569678A2 (en) 2005-09-07
WO2004047771A2 (en) 2004-06-10
CA2506813A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
BR0316523A (pt) Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
UY26130A1 (es) Compuestos para tratar la obesidad
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BRPI0518315B8 (pt) compostos de tiazol que modulam a atividade da proteína hsp90, métodos de inibição, tratamento e indução associados e composição farmacêutica
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
DE60329756D1 (de) Mitotische kinesin-hemmer
DE60329990D1 (de) Mitotische kinesin-hemmer
BRPI0414908A (pt) compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal
BR0214962A (pt) Composição para tratar distúrbios neurocerebrovasculares
BR0310092A (pt) Combinação de compostos orgânicos
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BR0108175A (pt) Derivados de piperazina e piperidina para o tratamento ou a prevenção de danos neuronais
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
BR112022005757A2 (pt) Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
BR0215395A (pt) Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
BRPI0414386A (pt) composto, métodos para fabricação do mesmo, para tratamento ou prevenção de uma doença, para ativação da função de er em uma célula óssea, para inibição de função de er em uma célula, para inibição da expressão de il-6, para inibição do crescimento de uma célula neoplásica expressando er, para prevenção de espermatogenese, para prevenção de um efeito reprodutivo adverso associados com exposição a uma falta de equilìbrio hormonal natural ou quìmica ambiental, e, composição

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.